SGLT2 Inhibition Reprograms Monocyte Metabolism to Attenuate Vascular Inflammation

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  Circulation  https://doi.org/10.1161/CIRCULATIONAHA.125.077432
Dr. B. Ilkin Safa et al.

Points

Vanderbilt Health researchers conducted a human clinical trial evaluating sixteen women with obesity and prediabetes to investigate the anti inflammatory effects of SGLT2 inhibition with empagliflozin.
Advanced sequencing revealed a significant reduction in circulating monocyte platelet aggregates within two weeks of treatment which further decreased after three months of daily empagliflozin therapy.
Comparative analysis against a low calorie diet cohort confirmed that leukocyte modulation occurred exclusively in the medication group independently of weight loss or caloric restriction alone.
Single cell evaluation documented metabolic reprogramming of monocytes shifting hyperinflammatory immune cells toward a stable cellular energy state focused on physiological vascular homeostasis.
Investigators initiated a follow up randomized placebo controlled trial enrolling seventy four patients to analyze immune alterations in both peripheral blood and visceral adipose tissue.

Summary

This study evaluated the anti-inflammatory and immunomodulatory effects of sodium-glucose cotransporter-2 (SGLT2) inhibition in patients with obesity and prediabetes. Published in Circulation by researchers at Vanderbilt Health, the open-label human trial provided the first direct clinical evidence of SGLT2 inhibitors altering circulating immune cells. The research sought to determine whether three months of empagliflozin administration could reduce monocyte-platelet aggregates (MPAs)—key cellular mediators of vascular inflammation and cardiovascular disease—and alter peripheral monocyte metabolic phenotypes beyond the effects of weight loss alone.

The investigator-initiated pilot trial enrolled 16 women with obesity and prediabetes who received empagliflozin for 12 weeks, comparing serial cellular measurements at two weeks and three months against a comparator cohort of women undergoing a three-month low-calorie diet. Advanced genetic sequencing and cellular imaging demonstrated a significant reduction in circulating MPAs within two weeks of empagliflozin initiation, with progressive suppression observed by week 12. Crucially, MPA reduction occurred exclusively in the empagliflozin group and was absent in diet-induced weight loss controls. Furthermore, single-cell analysis confirmed metabolic reprogramming of monocytes, shifting them from a hyperinflammatory phenotype toward an oxidative, baseline energy state.

The authors conclude that empagliflozin exerts specific, cellular-level immunomodulatory effects that decrease pro-inflammatory leukocyte-platelet interactions independently of glycemic control or caloric restriction. These findings demonstrate that SGLT2 inhibitors directly mitigate vascular inflammation, providing a novel biological mechanism underlying their established cardiovascular and renal protective benefits. To further evaluate these findings, a randomized, placebo-controlled clinical trial enrolling 74 participants with obesity and metabolic syndrome is currently underway at Vanderbilt Health to investigate both circulating and adipose tissue immune cell alterations.

Link to the article: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.125.077432

References

Safa, B. I., Oakes, J. M., Simmons, J. D., Nian, H., Kirk, L. A., Cassidy, A. C., Olson, E. C., Hatem, Z., Warren, C. M., Gonzalez, M. S., Amin, T., Sheng, Q., Matta, A., Zhu, L., Hairan, W., Howard, S. E., Flynn, C. R., Stier, M. T., Wilfong, E. M., … Mashayekhi, M. (2026). Sglt2 inhibitor empagliflozin reduces circulating monocyte-platelet aggregates: A pilot study. Circulation, 154(11), 1032–1035. https://doi.org/10.1161/CIRCULATIONAHA.125.077432